Company intelligence / Profile preview

CellPoint Systems

Leiden, North Holland, Netherlands

Ownership: Private
Employees: ~100
Development stage: Other

Overview

CellPoint is a biotechnology company specializing in the decentralized manufacturing of CAR-T cell therapies. The company's proprietary xCelo platform enables the rapid, point-of-care production of cell therapies within a hospital setting, significantly reducing the vein-to-vein turnaround time to approximately seven days. By automating and standardizing the manufacturing process, CellPoint aims to improve patient access and lower the costs associated with complex cell-based treatments. In 2022, the company was acquired by Galapagos NV to serve as the foundation for their decentralized cell therapy manufacturing network.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

LonzaThermo Fisher Scientific

Beyond the preview

Go deeper on CellPoint Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellPoint Systems.

Explore the full profile